Cargando…

Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway

Objectives. To evaluate the cost-effectiveness of etoricoxib (90 mg) relative to celecoxib (200/400 mg), and the nonselective NSAIDs naproxen (1000 mg) and diclofenac (150 mg) in the initial treatment of ankylosing spondylitis in Norway. Methods. A previously developed Markov state-transition model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jansen, Jeroen P., Taylor, Stephanie D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134091/ https://www.ncbi.nlm.nih.gov/pubmed/21772851 http://dx.doi.org/10.1155/2011/160326

Ejemplares similares

Efficacy of Etoricoxib, Celecoxib, Lumiracoxib, Non-Selective NSAIDs, and Acetaminophen in Osteoarthritis: A Mixed Treatment Comparison
por: Stam, WB, et al.
Publicado: (2012)

Efficacy of etoricoxib for ankylosing spondylitis: A protocol for systematic review of randomized controlled trial
por: Tang, Hua-yu, et al.
Publicado: (2019)

Balancing the gastrointestinal benefits and risks of nonselective NSAIDs
por: Peura, David A, et al.
Publicado: (2005)

Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients*
por: Walker, Chris, et al.
Publicado: (2016)

A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis
por: Balazcs, Eva, et al.
Publicado: (2016)

Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis
por: Hegazy, Ragia, et al.
Publicado: (2011)

Non-Steroidal Anti-Inflammatory Drug Etoricoxib Facilitates the Application of Individualized Exercise Programs in Patients with Ankylosing Spondylitis
por: Marcu, Iulia Rahela, et al.
Publicado: (2020)

Longitudinal Numbers-Needed-To-Treat (NNT) for Achieving Various Levels of Analgesic Response and Improvement with Etoricoxib, Naproxen, and Placebo in Ankylosing Spondylitis
por: Peloso, Paul M, et al.
Publicado: (2011)

Indirect comparison of NSAIDs for ankylosing spondylitis: Network meta-analysis of randomized, double-blinded, controlled trials
por: Fan, Meida, et al.
Publicado: (2020)

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo
por: Cannon, Christopher P, et al.
Publicado: (2008)

Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
por: Walker, Chris
Publicado: (2018)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Selective COX-2 inhibitor continues to be a safe alternative in patients with nonselective NSAIDs hypersensitivity
por: Thalappil, Sherin, et al.
Publicado: (2022)

Cardiopulmonary Manifestations of Ankylosing Spondylitis
por: Momeni, Mahnaz, et al.
Publicado: (2011)

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors
por: Carbo, Marlies J. G., et al.
Publicado: (2018)

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
por: Walker, Chris
Publicado: (2019)

Costs of Drug Therapy in Patients with Ankylosing Spondylitis in Brazil
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2016)

Etanercept/celecoxib on improving MRI inflammation of active ankylosing spondylitis: A multicenter, open-label, randomized clinical trial
por: Tu, Liudan, et al.
Publicado: (2022)

Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis
por: Lin, Tzu‐Chieh, et al.
Publicado: (2017)

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry
por: Sobel, Rachel E, et al.
Publicado: (2014)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Gastrointestinal Bleeding Rates Among Managed Care Patients Newly Started on COX-2 Inhibitors or Nonselective NSAIDs
por: Stockl, Karen, et al.
Publicado: (2005)

Cost Effectiveness of Secukinumab for the Treatment of Active Ankylosing Spondylitis in the UK
por: Emery, Paul, et al.
Publicado: (2018)

Ultrasonographic evaluation of enthesitis in patients with ankylosing spondylitis
por: Zhang, Huayong, et al.
Publicado: (2017)

Maintained activity in ankylosing spondylitis patients treated with TNFi and/or NSAID for at least 12 weeks: a cross-sectional study in Brazil
por: de Toledo, Ricardo Acayaba, et al.
Publicado: (2022)

Celecoxib and Etoricoxib may reduce risk of ischemic stroke in patients with rheumatoid arthritis: A nationwide retrospective cohort study
por: Chen, Acer I-Hung, et al.
Publicado: (2022)

Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007)

ASKyphoplan: a program for deformity planning in ankylosing spondylitis
por: van Royen, Barend J., et al.
Publicado: (2007)

Treat Ankylosing Spondylitis with Methazolamide
por: Chang, Xiaotian, et al.
Publicado: (2011)

Update on the treatment of ankylosing spondylitis
por: Maksymowych, Walter P
Publicado: (2007)

Ankylosing spondylitis: yesterday and today.
por: Spencer, D G, et al.
Publicado: (1980)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Ankylosing Spondylitis and Cardiac Abnormalities
por: Yang, Dong Heon
Publicado: (2012)

Spinal instability in ankylosing spondylitis
por: Badve, Siddharth A, et al.
Publicado: (2010)

Microbes, the gut and ankylosing spondylitis
por: Costello, Mary-Ellen, et al.
Publicado: (2013)

Advances in managing ankylosing spondylitis
por: Daikh, David I., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1jo68au3ce1v0g5sfr0jfrq99j